Official Position of the Brazilian Association of Bone Assessment and Metabolism (ABRASSO) on the evaluation of body composition by densitometry—part II (clinical aspects): interpretation, reporting, and special situations

Maeda, Sérgio Setsuo; Albergaria, Ben‐Hur; Szejnfeld, Vera Lúcia; Lazaretti‐Castro, Marise; Arantes, Henrique Pierotti; Ushida, Marcela; Domiciano, Diogo Souza; Pereira, Rosa Maria Rodrigues; Marin-Mio, Rosângela Villa; Oliveira, Mônica Longo de; Mendonça, Laura Maria Carvalho de; Prado, Mirley do; Souza, Guilherme Cardenaz de; Palchetti, Cecília Zanin; Sarni, Roseli Oselka Saccardo; Terreri, Maria Teresa; Castro, Luiz Cláudio; Artoni, Silvana Martinez Baraldi; Amoroso, Lizandra; Karcher, Débora Emy; Prado, Carla M.; González, Marı́a Cristina; Pinheiro, Marcelo de Medeiros

doi:10.1186/s42358-022-00240-9

Cited by 5 publications

(6 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors stated that the data on ALM remain inconclusive because the studies reported the results inconsistently across upper or lower skeletal regions. The ALMI used in the present study, which is an adjusted ratio of ALM to height, is a validated criterion for assessing lean mass that has shown a consistent correlation with muscle mass throughout life [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lean mass and associated factors in women with PCOS with different phenotypes

Fighera,

dos Santos,

Spritzer

2023

PLoS ONE

View full text Add to dashboard Cite

Although current evidence suggests increased risk of obesity, insulin resistance, and metabolic alterations in patients with polycystic ovary syndrome (PCOS), especially of a hyperandrogenic phenotype, the impact of each one of these variables on muscle mass remains uncertain. In this case-control study, we evaluated clinical and hormonal characteristics related to lean body mass according to the different PCOS phenotypes. We performed clinical, metabolic, and hormonal assessments and evaluated body compartments by dual-energy X-ray absorptiometry in 133 women of reproductive age. Creatinine served as an indirect marker of lean mass. Median age was 28 (range, 17–37) years. Women with phenotypes A and B (n = 59) had higher body mass index (BMI) and metabolic syndrome prevalence than those with phenotype C (n = 23) and controls (n = 51) (p<0.005). Women with phenotypes A and B also had higher Ferriman-Gallwey score (p<0.001), insulin levels (p = 0.006), HOMA-IR (p = 0.008), testosterone (p = 0.008), free androgen index (FAI) (p<0.001), fat mass index (FMI) (p = 0.015), android-to-gynoid fat ratio (p = 0.036), and bone mineral density (BMD) at lumbar spine (p = 0.027) and total femur (p = 0.013) than controls. Median appendicular lean mass index (ALMI) was higher in phenotypes A and B than in controls (7.01 [IQR, 6.33–8.02] vs. 6.69 [IQR, 5.94–7.09], p = 0.024), but it did not differ significantly from that in phenotype C (6.60 [IQR, 6.16–7.22], p = 0.222). Even after adjusting for BMI, ALMI correlated positively with creatinine in women with phenotypes A and B (rho = 0.319, p = 0.023) but not in those with phenotype C (p = 0.238) or controls (p = 0.097). In multivariate linear regression analyses, ALMI was positively associated with insulin, FAI, FMI, and total femur BMD. The present results suggest that fasting insulin, FAI, fat mass, and total femur BMD were positively associated with increased lean mass in women with PCOS phenotypes A and B.

show abstract

Section: Discussionmentioning

confidence: 99%

“…ALMI was obtained as the ratio of ALM to height 2 . An FMI of 6–9 kg/m 2 and an ALMI ≥ 5.45 kg/m 2 were considered normal body fat [ 26 ].…”

Section: Methodsmentioning

confidence: 99%

Lean mass and associated factors in women with PCOS with different phenotypes

Fighera,

dos Santos,

Spritzer

2023

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…This region, also called android region, comprises the area located between the ribs and pelvis, with demarcation greater than 20% of the distance between the iliac crest and the neck and a lower demarcation at the top of the pelvis. 14 …”

Section: Methodsmentioning

confidence: 99%

“…The DXA execution method is safe, using low-intensity X-rays, which allows to measure bone mass, LM and FM individually. 14,15 Some studies show a significant increase in LM throughout the treatment, at the end of the follow-up period, and in comparison with the control group, with the effect being more evident in boys and during the first year of treatment. The main determinant of reported LM gain is length, as growth recovery was accompanied by an increase in LM, especially during the first year of treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of treatment with growth hormone on body composition and metabolic profile of short children born small for gestational age

Kühl,

Dias,

Pereira

2024

Rev. paul. pediatr.

View full text Add to dashboard Cite

Objective: To assess the effect of recombinant growth hormone (rGH) on body composition and metabolic profile of prepubertal short children born small for gestational age (SGA) before and after 18 months of treatment. Methods: It is a clinical, non-randomized, and paired study. Children born SGA, with birth weight and/or length <-2 standard deviations (SD) for gestational age and sex, prepubertal, born at full term, of both genders, with the indication for treatment with rGH were included. The intervention was performed with biosynthetic rGH at doses ranging from 0.03 to 0.05 mg/kg/day, administered subcutaneously, once a day at bedtime. Total lean mass (LM) and total fat mass (FM) were carried out using dual-energy X-ray absorptiometry (DXA), and the metabolic profile was assessed for insulin, glycemia, IGF-1 levels and lipid profile. Results: Twelve patients (nine girls, 8.17±2.39 y) were evaluated; three patients dropped out of the study. There was an increase of LM adjusted for length (LMI) (p=0.008), LMI standard deviation score (SDS) adjusted for age and sex (p=0.007), and total LM (p<0.001). The percentage of body fat (BF%) and abdominal fat (AF) remained unaltered in relation to the beginning of treatment. Among the metabolic variables, blood glucose remained within normal levels, and there was a reduction in the number of participants with altered cholesterol (p=0.023). Conclusions: The effect of rGH treatment was higher on LM than in FM, with increased LM adjusted for length and standardized for age and sex. Glycemia remained within the normal limits, and there was a decreased number of children with total cholesterol above the recommended levels.

show abstract